Advice
following an abbreviated submission:
palonosetron soft capsules (Aloxi®) is accepted for use within NHS Scotland.
Indication under review: prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
At recommended licensed doses the soft capsule formulation has been shown to be clinically non-inferior to the intravenous formulation and is cost neutral.
SMC has previously accepted palonosetron intravenous injection for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Download detailed advice40KB (PDF)
Medicine details
- Medicine name:
- palonosetron (Aloxi)
- SMC ID:
- 838/13
- Indication:
- For the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
- Pharmaceutical company
- Sinclair IS Pharma
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 February 2013